Literature DB >> 2580136

Cardiovascular effects of the metabolites of diltiazem in dogs.

H Yabana, T Nagao, M Sato.   

Abstract

The effects of diltiazem and some of its metabolites on the cardiovascular system were studied in anesthetized dogs and in blood-perfused canine papillary muscles. The metabolites included N-desmethyldiltiazem (MA), a newly discovered major metabolite; desacetyldiltiazem (M1); desacetyl MA (M2); O-desmethyl M1 (M4); and O-desmethyl M2 (M6). In the anesthetized dog, diltiazem and its metabolites produced a dose-dependent increase in coronary blood flow, decreases in blood pressure and heart rate, and an increase in left ventricular dP/dtmax. The ranking of coronary-vasodilating activity of diltiazem and its metabolites, in decreasing order, was diltiazem, M1, MA, M2, M4, and M6. The effects of the metabolites were more selective for coronary vasodilation than for hypotension, but their selectivities were less than that of diltiazem. Coronary vasodilation and hypotension with diltiazem and MA were of longer duration than those with their corresponding desacetyl metabolites. By close arterial administration to the blood-perfused canine papillary muscle preparation, diltiazem and its metabolites also produced coronary-vasodilating actions, whereas the negative inotropic actions were very weak. The present study revealed that the cardiovascular properties of some of diltiazem's metabolites are qualitatively the same as those of diltiazem, but the activity of diltiazem is the most potent, and MA is less active than M1.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2580136     DOI: 10.1097/00005344-198501000-00025

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  15 in total

1.  Performance of diltiazem tablet and multiparticulate osmotic formulations in the dog.

Authors:  S C Sutton; K Engle; R A Deeken; K E Plute; R D Shaffer
Journal:  Pharm Res       Date:  1990-08       Impact factor: 4.200

2.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

3.  The solubility-modulated osmotic pump: in vitro/in vivo release of diltiazem hydrochloride.

Authors:  G A McClelland; S C Sutton; K Engle; G M Zentner
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

4.  N-monodesmethyldiltiazem is the predominant metabolite of diltiazem in the plasma of young and elderly hypertensives.

Authors:  S C Montamat; D R Abernethy
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

5.  Metabolism of diltiazem in hepatic and extrahepatic tissues of rabbits: in vitro studies.

Authors:  W Homsy; M Lefebvre; G Caillé; P du Souich
Journal:  Pharm Res       Date:  1995-04       Impact factor: 4.200

6.  Pharmacokinetics and hypotensive effect of deacetyl N-monodesmethyl diltiazem (M2) in rabbits after a single intravenous administration.

Authors:  P K Yeung; J D Feng; S J Buckley
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jan-Mar       Impact factor: 2.441

7.  Pharmacokinetics and metabolism of diltiazem in rabbits after a single intravenous or single oral administration.

Authors:  P K Yeung; S J Mosher; P T Pollak
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

Review 8.  Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.

Authors:  H Echizen; M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

Review 9.  Metabolites of antihypertensive drugs. An updated review of their clinical pharmacokinetic and therapeutic implications.

Authors:  A Ebihara; A Fujimura
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

10.  Diltiazem pharmacokinetics in the rat and relationship between its serum concentration and uterine and cardiovascular effects.

Authors:  S J Downing; D Edwards; M Hollingsworth
Journal:  Br J Pharmacol       Date:  1987-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.